About NBR“Nightly Business Report produced by CNBC” (NBR) is an award-winning and highly-respected nightly business news program that airs on public television. Television’s longest-running evening business news broadcast, “NBR” features in-depth coverage and analysis of the biggest financial news stories of the day and access to some of the world’s top business leaders and policy makers.
- Professional cornhole has turned a tailgating game into a hit TV sport – and it's expanding globally
- The bull isn't done yet, chart watching 'godfather' says, with the Dow flashing 2 big signs
- Why Justin Thomas says golf has Tiger Woods to thank for 'unbelievable' prize money, attention
- Trump acknowledges White House counsel McGahn has cooperated with Mueller, denounces 'witch hunt'
- Account fees can doom your retirement savings. Here's how to avoid them.
NBR on TwitterMy Tweets
Subscribe to RSS
Biotech & Pharmaceuticals
Meg Tirrell reports on J&J’s relaunch of the iconic baby brand, which will have fewer chemicals and more natural ingredients.
J&J is still the global leader in the category, but says it needs to make a change to stem a sales decline.
Shkreli, who gained infamy for raising the price of the drug Daraprim by more than 5,000 percent, has been locked up since offering a bounty for hair stolen by Facebook followers from the head of Hillary Clinton.
Since President Trump took office, drugmakers have hiked list prices on hundreds of drugs at rates that outpace inflation, Axios reports.
Celgene agrees to buy biotechnology company Juno Therapeutics for about $9 billion.
Sixty-four percent of patients achieved major depressive disorder remission using SAGE-217 in the 15th day of treatment, Sage says.
Inter partes review is at the center of a case before the Supreme Court, and the decision will have far-reaching effects.
The approvals “mark another significant milestone for our company,” Mylan CEO Heather Bresch says.
Arena Pharmaceuticals’ drug Ralienpag met its Phase 2 program goals.
Lilly says the FDA needed additional data to “characterize safety concerns across treatment arms.”
While the White House and Congress struggled to repeal Obamacare, investors did not shy away from health-care stocks in the first quarter.
Drug maker Mylan said it was recalling select lots of the company’s EpiPen device due to a potential defect.
United Therapeutics said it would be delaying the launch of an implantable pump until 2018.
The track record in drug development for Alzheimer’s disease has been terrible: a success rate of less than 1 percent.
Almost 200,000 people have fatally overdosed on opioids in the past 15 years, with more than 30,000 people dying in 2015 alone.